Fette Andreas
Medical School, University of Pécs, Hungary.
ScientificWorldJournal. 2013 May 20;2013:850193. doi: 10.1155/2013/850193. Print 2013.
In 2008, the positive effects of propranolol on infantile hemangiomas (IH) have been discovered serendipitously by Léauté-Labrèze and her coworkers. Since then, propranolol has been in use in allday clinical practice worldwide for treatment of IH. It even caused some kind of paradigm shift in the overall management of these lesions, though propranolol is still not FDA approved, respectively, in "off-label" use for this indication in the majority of institutions. Thus, the aim of this communication is to evaluate the literature for current evidence regarding guidelines for preassessment and standards of care before initiation of therapy.
2008年,勒奥特 - 拉布雷兹及其同事意外发现了普萘洛尔对婴儿血管瘤(IH)的积极作用。从那时起,普萘洛尔在全球范围内的日常临床实践中一直用于治疗IH。尽管普萘洛尔仍未获得美国食品药品监督管理局(FDA)的批准,在大多数机构中属于该适应症的“超说明书”用药,但它甚至在这些病变的整体管理中引起了某种范式转变。因此,本交流的目的是评估文献,以获取有关治疗开始前预评估指南和护理标准的当前证据。